These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

313 related items for PubMed ID: 17566666

  • 1. Stem cell regulation and the development of blast crisis in chronic myeloid leukemia: Implications for the outcome of Imatinib treatment and discontinuation.
    Wodarz D.
    Med Hypotheses; 2008; 70(1):128-36. PubMed ID: 17566666
    [Abstract] [Full Text] [Related]

  • 2. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
    Barnes DJ, Palaiologou D, Panousopoulou E, Schultheis B, Yong AS, Wong A, Pattacini L, Goldman JM, Melo JV.
    Cancer Res; 2005 Oct 01; 65(19):8912-9. PubMed ID: 16204063
    [Abstract] [Full Text] [Related]

  • 3. Chronic myeloid leukemia blast crisis arises from progenitors.
    Michor F.
    Stem Cells; 2007 May 01; 25(5):1114-8. PubMed ID: 17218393
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Imatinib resistance and progression of CML to blast crisis: somatic hypermutation AIDing the way.
    Strout MP, Schatz DG.
    Cancer Cell; 2009 Sep 08; 16(3):174-6. PubMed ID: 19732715
    [Abstract] [Full Text] [Related]

  • 6. Imatinib activity in vitro in tumor cells from patients with chronic myeloid leukemia in chronic phase and blast crisis.
    Olsson-Strömberg U, Aleskog A, Björnberg A, Höglund M, Simonsson B, Bengtsson M, Barbany G, Larsson R, Lindhagen E.
    Anticancer Drugs; 2006 Jul 08; 17(6):631-9. PubMed ID: 16917208
    [Abstract] [Full Text] [Related]

  • 7. [Clinical efficacy and side effects of STI571 in treatment of patients with chronic myeloid leukemia].
    Liu XL, Zhou SY, Du QF, Zheng WY, Zhang S, Song LL, Xu B, Liu QF, Meng FY.
    Ai Zheng; 2004 Apr 08; 23(4):421-5. PubMed ID: 15087031
    [Abstract] [Full Text] [Related]

  • 8. Durable molecular response to imatinib mesylate following nonmyeloablative allogeneic stem-cell transplantation for persisting myeloid blast crisis in chronic myeloid leukemia.
    Staber PB, Brezinschek R, Linkesch W, Sill H, Neumeister P.
    Haematologica; 2003 Aug 08; 88(8):ECR29. PubMed ID: 12935988
    [Abstract] [Full Text] [Related]

  • 9. Promyelocytic blast crisis of chronic myeloid leukemia during imatinib treatment.
    Chung HJ, Chi HS, Cho YU, Park CJ, Seo EJ, Kim KH, Lee JH.
    Ann Clin Lab Sci; 2008 Aug 08; 38(3):283-6. PubMed ID: 18715859
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Imatinib mesylate in chronic myeloid leukemia: a prospective, single arm, non-randomized study.
    Deshmukh C, Saikia T, Bakshi A, Amare-Kadam P, Baisane C, Parikh P.
    J Assoc Physicians India; 2005 Apr 08; 53():291-5. PubMed ID: 15987013
    [Abstract] [Full Text] [Related]

  • 13. Imatinib mesylate-sensitive blast crisis immediately after discontinuation of imatinib mesylate therapy in chronic myelogenous leukemia: report of two cases.
    Higashi T, Tsukada J, Kato C, Iwashige A, Mizobe T, Machida S, Morimoto H, Ogawa R, Toda Y, Tanaka Y.
    Am J Hematol; 2004 Jul 08; 76(3):275-8. PubMed ID: 15224366
    [Abstract] [Full Text] [Related]

  • 14. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up.
    Palandri F, Castagnetti F, Testoni N, Luatti S, Marzocchi G, Bassi S, Breccia M, Alimena G, Pungolino E, Rege-Cambrin G, Varaldo R, Miglino M, Specchia G, Zuffa E, Ferrara F, Bocchia M, Saglio G, Pane F, Alberti D, Martinelli G, Baccarani M, Rosti G, GIMEMA Working Party on Chronic Myeloid Leukemia.
    Haematologica; 2008 Dec 08; 93(12):1792-6. PubMed ID: 18838477
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Chronic phase of ETV6-ABL1 positive CML responds to imatinib.
    Kawamata N, Dashti A, Lu D, Miller B, Koeffler HP, Schreck R, Moore S, Ogawa S.
    Genes Chromosomes Cancer; 2008 Oct 08; 47(10):919-21. PubMed ID: 18615681
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [A case of chronic myelogenous leukemia responding to imatinib mesilate (Glivec) after relapse of blastic crisis following allogeneic bone marrow transplantation].
    Fujisawa S, Yano K, Kobayashi M.
    Gan To Kagaku Ryoho; 2003 Mar 08; 30(3):427-30. PubMed ID: 12669406
    [Abstract] [Full Text] [Related]

  • 20. Imatinib and bortezomib induce the expression and distribution of anaphase-promoting complex adaptor protein Cdh1 in blast crisis of chronic myeloid leukemia.
    Wang Q, Zhou HS, Huang KK, Jiang XJ, Wu FQ, Cao R, Yin CX, Liao LB, Zheng ZX, He H, Lin R, Yi ZS, Xu D, Yang M, Meng FY.
    Int J Oncol; 2012 Feb 08; 40(2):418-26. PubMed ID: 22002244
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.